Pier Capital, LLC Regenxbio Inc. Transaction History

Pier Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$27.01 - $40.26 $2.55 Million - $3.8 Million	-94,433 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$27.75 - $43.44 $389,887 - $610,332	-14,050 Reduced 12.95%	94,433 $3.48 Million
Q1 2020 May 15, 2020	BUY	$21.5 - $54.2 $419,658 - $1.06 Million	19,519 Added 21.94%	108,483 $3.51 Million
Q4 2019 Feb 14, 2020	SELL	$34.54 - $44.87 $1 Million - $1.31 Million	-29,091 Reduced 24.64%	88,964 $3.65 Million
Q3 2019 Nov 13, 2019	BUY	$31.84 - $50.88 $306,842 - $490,330	9,637 Added 8.89%	118,055 $4.2 Million
Q2 2019 Aug 14, 2019	SELL	$42.0 - $59.29 $959,280 - $1.35 Million	-22,840 Reduced 17.4%	108,418 $5.57 Million
Q1 2019 Apr 24, 2019	BUY	$40.82 - $62.45 $2.73 Million - $4.18 Million	66,993 Added 104.24%	131,258 $7.52 Million
Q4 2018 Feb 13, 2019	SELL	$39.11 - $75.15 $1.18 Million - $2.27 Million	-30,227 Reduced 31.99%	64,265 $2.7 Million
Q3 2018 Nov 14, 2018	SELL	$65.0 - $82.15 $1.45 Million - $1.83 Million	-22,321 Reduced 19.11%	94,492 $7.13 Million
Q2 2018 Aug 08, 2018	BUY	$27.2 - $74.35 $3.18 Million - $8.69 Million	116,813 New	116,813 $8.38 Million

196

43M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $313M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.